Over the past five years, Valeant Pharmaceuticals' (NYSE:VRX) stock is up 856%, absolutely smashing the returns delivered by the market. The company has recently made further waves by teaming up with activist investor Bill Ackman's Pershing Square Capital in a bid to take over Allergan (NYSE:AGN), the specialty pharma company famous for Botox.
In the following video, Motley Fool analysts Michael Douglass and Brendan Mathews discuss Valeant's unique business model. As Brendan explains, Valeant only invests a relatively small amount in research and development. According to management, the returns on investing in research simply aren't high enough in most cases. Management believes it can get a better return by purchasing proven drugs or companies with existing product portfolios. It's a lot less risky, and the returns, especially if acquisitions are made judiciously, are much higher than investing in drug development. Michael points out that this isn't a totally new strategy -- Pfizer (NYSE:PFE), for instance, hasn't been shy about making acquisitions. But Valeant has definitely taken cost-cutting to the next level with its R&D reductions.
Brendan Mathews owns shares of Valeant Pharmaceuticals. Michael Douglass has no position in any stocks mentioned. The Motley Fool owns and recommends shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Valeant Pharmaceuticals' Stellar 43% Gain in 2017, Explained
Wall Street rewards the embattled Valeant after the company met numerous goals last year.
3 Compelling Reasons Valeant Pharmaceuticals Exploded Higher by 24% in December
Valeant took another step forward on its road to redemption, but it still has a long walk ahead.
Billionaire George Soros Is Betting Big Against These 2 Pharma Stocks
Can Valeant and Teva rebound? George Soros' namesake fund doesn't seem to think so.